Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in Japanese patients with medullary thyroid carcinoma
NCT01661179Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vandetanib in medullary thyroid carcinoma (MTC), sponsored by Sanofi. Primary endpoint: Objective Response Rate at 56 weeks. Started Nov 2012; status: completed.
02
Drugs
vandetanib
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT01661179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661179.